Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ABCMNASDAQ:CRSPNYSE:DNANASDAQ:PCVX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABCMAbcam$23.99$23.88$12.48▼$25.32$5.50B0.863.08 million shs3,300 shsCRSPCRISPR Therapeutics$47.49+1.7%$39.48$30.04▼$63.68$4.10B1.751.85 million shs15.07 million shsDNAGinkgo Bioworks$9.42-2.0%$7.89$5.00▼$16.85$551.18M1.251.42 million shs7.04 million shsPCVXVaxcyte$32.58-0.9%$33.26$27.66▼$121.06$4.20B1.21.46 million shs5.90 million shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABCMAbcam0.00%0.00%0.00%0.00%0.00%CRSPCRISPR Therapeutics0.00%+7.32%+31.77%+39.55%-12.07%DNAGinkgo Bioworks0.00%+10.36%+35.30%+65.07%-29.58%PCVXVaxcyte0.00%-0.88%-0.06%-13.72%-56.85%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationABCMAbcamN/AN/AN/AN/AN/AN/AN/AN/ACRSPCRISPR Therapeutics2.924 of 5 stars4.31.00.00.01.92.50.6DNAGinkgo Bioworks0.7913 of 5 stars0.82.00.00.01.82.51.3PCVXVaxcyte2.7802 of 5 stars4.61.00.00.02.71.70.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceABCMAbcam 0.00N/AN/AN/ACRSPCRISPR Therapeutics 2.53Moderate Buy$71.7551.08% UpsideDNAGinkgo Bioworks 1.67Reduce$5.77-38.76% DownsidePCVXVaxcyte 3.10Buy$136.50318.97% UpsideCurrent Analyst Ratings BreakdownLatest PCVX, DNA, CRSP, and ABCM Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/27/2025CRSPCRISPR TherapeuticsPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$105.006/27/2025CRSPCRISPR TherapeuticsJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Outperform ➝ Market Outperform$86.006/27/2025CRSPCRISPR TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$65.006/26/2025CRSPCRISPR TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$81.006/26/2025CRSPCRISPR TherapeuticsChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$82.005/21/2025CRSPCRISPR TherapeuticsJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Outperform ➝ Market Outperform$86.00 ➝ $86.005/20/2025CRSPCRISPR TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$81.00 ➝ $81.005/20/2025CRSPCRISPR TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$65.00 ➝ $65.005/9/2025CRSPCRISPR TherapeuticsBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetEqual Weight ➝ Equal Weight$56.00 ➝ $42.005/8/2025CRSPCRISPR TherapeuticsThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$53.00 ➝ $47.004/22/2025PCVXVaxcyteCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight(Data available from 6/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookABCMAbcam$379.70M14.49$0.60 per share40.17$3.92 per share6.12CRSPCRISPR Therapeutics$37.31M109.92N/AN/A$22.64 per share2.10DNAGinkgo Bioworks$227.04M2.43N/AN/A$13.17 per share0.72PCVXVaxcyteN/AN/AN/AN/A$26.52 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateABCMAbcam-$10.51MN/A0.0042.092.19N/AN/AN/AN/ACRSPCRISPR Therapeutics-$366.25M-$4.52N/AN/AN/A-1,023.64%-20.08%-17.13%8/4/2025 (Estimated)DNAGinkgo Bioworks-$547.03M-$9.16N/AN/AN/A-198.84%-52.35%-27.14%8/14/2025 (Estimated)PCVXVaxcyte-$463.93M-$3.99N/AN/AN/AN/A-17.12%-16.26%8/5/2025 (Estimated)Latest PCVX, DNA, CRSP, and ABCM EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2025Q1 2025PCVXVaxcyte-$1.02-$1.04-$0.02-$1.04N/AN/A5/6/2025Q1 2025CRSPCRISPR Therapeutics-$1.27-$1.58-$0.31-$1.58N/AN/A5/6/2025Q1 2025DNAGinkgo Bioworks-$1.23-$1.58-$0.35-$1.68$38.70 million$48.32 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthABCMAbcamN/AN/AN/AN/AN/ACRSPCRISPR TherapeuticsN/AN/AN/AN/AN/ADNAGinkgo BioworksN/AN/AN/AN/AN/APCVXVaxcyteN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioABCMAbcamN/A1.351.00CRSPCRISPR TherapeuticsN/A15.6415.64DNAGinkgo BioworksN/A4.884.88PCVXVaxcyteN/A17.7017.70Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipABCMAbcam90.45%CRSPCRISPR Therapeutics69.20%DNAGinkgo Bioworks78.63%PCVXVaxcyte96.78%Insider OwnershipCompanyInsider OwnershipABCMAbcam6.73%CRSPCRISPR Therapeutics4.10%DNAGinkgo Bioworks9.72%PCVXVaxcyte3.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableABCMAbcam1,760229.27 million213.84 millionOptionableCRSPCRISPR Therapeutics47386.36 million82.82 millionOptionableDNAGinkgo Bioworks64058.53 million52.84 millionOptionablePCVXVaxcyte160129.00 million125.01 millionOptionablePCVX, DNA, CRSP, and ABCM HeadlinesRecent News About These CompaniesVaxcyte, Inc. (NASDAQ:PCVX) Given Average Recommendation of "Buy" by Brokerages3 hours ago | marketbeat.comGAMMA Investing LLC Purchases 9,422 Shares of Vaxcyte, Inc. (NASDAQ:PCVX)June 21, 2025 | marketbeat.comAssenagon Asset Management S.A. Buys New Position in Vaxcyte, Inc. (NASDAQ:PCVX)June 14, 2025 | marketbeat.comVaxcyte, Inc. (NASDAQ:PCVX) Shares Bought by Rhumbline AdvisersJune 12, 2025 | marketbeat.comBrokers Offer Predictions for Vaxcyte FY2026 EarningsJune 11, 2025 | marketbeat.comVaxcyte: Sentiment Is Pushing The Shares DownJune 10, 2025 | seekingalpha.comVaxcyte, Inc. (NASDAQ:PCVX) Given Consensus Rating of "Buy" by AnalystsJune 5, 2025 | marketbeat.com103,683 Shares in Vaxcyte, Inc. (NASDAQ:PCVX) Purchased by Universal Beteiligungs und Servicegesellschaft mbHJune 1, 2025 | marketbeat.comCalifornia State Teachers Retirement System Has $8.60 Million Stock Position in Vaxcyte, Inc. (NASDAQ:PCVX)June 1, 2025 | marketbeat.comVaxcyte (NASDAQ:PCVX) Stock Price Up 5.7% - Should You Buy?May 30, 2025 | marketbeat.comHere’s Why Vaxcyte (PCVX) Sold Off in Q1May 27, 2025 | msn.comIs Vaxcyte, Inc. (PCVX) The Best Stock That Will Bounce Back?May 9, 2025 | insidermonkey.comVaxcyte Reports First Quarter 2025 Financial Results and Provides Business UpdateMay 7, 2025 | globenewswire.comVaxcyte appoints new independent directorMay 3, 2025 | uk.investing.comVaxcyte Appoints Dr. Olivier Brandicourt to BoardMay 1, 2025 | tipranks.comVaxcyte, Inc. Appoints Dr. Olivier Brandicourt to Board of Directors to Advance Vaccine DevelopmentMay 1, 2025 | quiverquant.comQVaxcyte Appoints Dr. Olivier Brandicourt to Board of DirectorsMay 1, 2025 | globenewswire.comIs Vaxcyte, Inc. (PCVX) the Best Oversold NASDAQ Stock to Buy Right Now?April 29, 2025 | insidermonkey.comCommit To Buy Vaxcyte At $20, Earn 14.7% Annualized Using OptionsApril 23, 2025 | nasdaq.comCantor Fitzgerald Initiates Coverage of Vaxcyte (PCVX) with Overweight RecommendationApril 23, 2025 | msn.comTD Cowen Keeps Their Buy Rating on Vaxcyte (PCVX)April 22, 2025 | markets.businessinsider.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimePCVX, DNA, CRSP, and ABCM Company DescriptionsAbcam NASDAQ:ABCMAbcam plc, a life science company, focuses on identifying, developing, and distributing reagents and tools for scientific research, diagnostics, and drug discovery. The company's principal products include primary and secondary antibodies; conjugated antibodies and conjugation kits; singleplex immunoassays; proteins and peptides that include cytokines; edited cell lines and lysates; and various other products, including cellular activity kits, biochemicals, and cell signaling pathway tools. It serves scientists and researchers in academic institutions and research institutes, as well as in pharmaceutical, biotechnology, and diagnostics companies. The company has operations in the Americas, Europe, the Middle East, Africa, China, Japan, and rest of the Asia Pacific. It sells its products online. The company was incorporated in 1998 and is headquartered in Cambridge, the United Kingdom.CRISPR Therapeutics NASDAQ:CRSP$47.49 +0.79 (+1.69%) Closing price 06/27/2025 04:00 PM EasternExtended Trading$48.26 +0.77 (+1.61%) As of 04:43 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic collaborations with companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in San Francisco, California and London, United Kingdom. For more information, please visit www.crisprtx.com.Ginkgo Bioworks NYSE:DNA$9.42 -0.19 (-2.01%) Closing price 06/27/2025 03:59 PM EasternExtended Trading$9.98 +0.56 (+5.93%) As of 04:43 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops platform for cell programming in the United States. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. It serves pharma and biotech, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.Vaxcyte NASDAQ:PCVX$32.58 -0.30 (-0.91%) Closing price 06/27/2025 04:00 PM EasternExtended Trading$32.46 -0.12 (-0.38%) As of 04:05 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Nike Stock: The Mother of All Comebacks Might Have Just Begun EA Just Caught a Monster Upgrade: Bullish Breakout Ahead? Snowflake Hits 52-Week High—Options Traders Bet on Further Rally Addition by Subtraction: Intel’s New Strategy Energizes Investors Apple: The Mag 7’s Dead Money Stock or AI Cash Cow in the Making? NVIDIA’s Stock Price Hits New Highs: This Is What’s Next Micron: A Hot Buy Heats Up, Fresh All-Time Highs Are Coming Rocket Lab: Europe Comes Calling as Momentum Builds Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
